| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
Omeprazole sulfide targets the gastric H⁺/K⁺ ATPase (proton pump) in gastric parietal cells. As a metabolite of omeprazole, it functions as a proton pump inhibitor, blocking the final step of gastric acid secretion. Its mechanism is similar to that of omeprazole and other proton pump inhibitors.
|
|---|---|
| ln Vitro |
In vitro, Omeprazole sulfide functions as a proton pump inhibitor. It is a metabolite of omeprazole and retains activity against the gastric H⁺/K⁺ ATPase. It is used as a precursor in the synthesis of esomeprazole. Its in vitro activity is characteristic of benzimidazole proton pump inhibitors.
|
| ln Vivo |
In vivo, Omeprazole sulfide is the active metabolite of omeprazole and contributes to the acid-suppressing effects of the parent drug. It accumulates in the acidic environment of the gastric parietal cell canaliculus and covalently binds to the H⁺/K⁺ ATPase, irreversibly inhibiting gastric acid secretion.
|
| Enzyme Assay |
In vitro assays for Omeprazole sulfide are typically analytical in nature. High-performance liquid chromatography (HPLC) or ultra-performance liquid chromatography (UPLC) with UV detection is used to quantify the metabolite in plasma, urine, or pharmaceutical formulations. Mass spectrometry (LC-MS/MS) may also be used for identification and quantification.
|
| Cell Assay |
Cellular assays for Omeprazole sulfide are not typically performed, as the compound acts on the H⁺/K⁺ ATPase in gastric parietal cells. Studies may use gastric parietal cell preparations or cell lines expressing the H⁺/K⁺ ATPase to assess acid secretion inhibition.
|
| Animal Protocol |
In vivo animal studies for Omeprazole sulfide are limited, as it is a metabolite rather than a primary therapeutic agent. Studies would focus on its role in the pharmacokinetics and pharmacodynamics of omeprazole.
|
| ADME/Pharmacokinetics |
Omeprazole sulfide is a metabolite of omeprazole and is primarily produced in the liver by CYP450 enzymes. It has a longer half-life than omeprazole and contributes to the acid-suppressing effects of the parent drug. It is not administered as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
Omeprazole sulfide is generally well-tolerated as a metabolite of omeprazole. Its safety profile is similar to that of omeprazole, which includes gastrointestinal disturbances and, rarely, more serious adverse effects.
|
| Additional Infomation |
Omeprazole sulfides belong to the benzimidazole class of compounds.
Omeprazole sulfide (Ufiprazole) is an active metabolite of the proton pump inhibitor omeprazole. It functions as a proton pump inhibitor. It is used as a reference standard in pharmaceutical analysis and as a precursor in the synthesis of esomeprazole. It is not a drug and has no clinical approval. |
| Molecular Formula |
C17H19N3O2S
|
|---|---|
| Molecular Weight |
329.4167
|
| Exact Mass |
329.119
|
| CAS # |
73590-85-9
|
| Related CAS # |
Omeprazole;73590-58-6
|
| PubChem CID |
155794
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
539.7±60.0 °C at 760 mmHg
|
| Melting Point |
124 °C
|
| Flash Point |
280.2±32.9 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.649
|
| LogP |
3.87
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
23
|
| Complexity |
387
|
| Defined Atom Stereocenter Count |
0
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~303.56 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.59 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.59 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.59 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0356 mL | 15.1782 mL | 30.3564 mL | |
| 5 mM | 0.6071 mL | 3.0356 mL | 6.0713 mL | |
| 10 mM | 0.3036 mL | 1.5178 mL | 3.0356 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
